Abstract: Systems and methods of reducing airborne contaminants, such as airborne microorganisms, including bacterial, viral, and fungal microbes, in an indoor space are disclosed. The method includes positioning a portable photo-catalytic oxidation system proximate a source of contaminants in the indoor space and activating the photo-catalytic oxidation system to circulate air through the photo-catalytic oxidation system at a rate ranging from approximately 16 to approximately 24 air exchanges per hour in the indoor space. The photo-catalytic oxidation system is configured to oxidize contaminates in the air.

Abstract: A backrest device that normally supports an occupant and moves forward with the occupant during a forward impact/crash event. The device is equipped with a spring activated biased ratcheting mechanism that provides only forward movement, thus reducing the amount of dangerous rear excursion during the rebound phase, as measured by the occupant's head and torso.

Abstract: A wheelchair includes: a chassis configured to collapse in a width direction of the wheelchair; at least one wheel carried by the chassis; a seat assembly including a seat and a back support carried by the chassis, the back support defining a tilt angle relative to the seat and being pivotable to adjust the tilt angle; and a tilt assembly carried by the chassis and including at least one tilt actuator coupled to the back support, the at least one tilt actuator being configured to pivot the back support and adjust the tilt angle. The chassis is collapsible in the width direction while carrying the at least one actuator to reduce a width of the wheelchair.

Abstract: The present invention relates to a system (100) for preventing pressure wounds. The system (100) comprises a pump (4) for supplying or evacuating air to or from a mattress (2). The mattress (2) comprises at least two air channel systems (8) and a hose (6). The hose (6) comprises a connector unit (10) at the distal end for connecting the mattress (2) to a receiving unit (12) provided on the pump (4). The connector unit (10) is provided with an information carrier (54) carrying information, which is readable by the pump (4), for operating the at least two channel systems (8) independently of each other.

Abstract: A patient slider device configured to move a patient from a first bed surface to a second bed surface positioned adjacent thereto. The patient slider device includes a frame, a bed engagement assembly and a patient pulling assembly. The bed engagement assembly includes a bumper with the bumper being adjustable relative to the frame. The patient pulling assembly includes a winch assembly, preferably positioned proximate a lower end of the frame, and a sheet engaging clamp assembly. The sheet engaging clamp assembly includes a base member and a locking member structurally configured to clamp a sheet therebetween.

Abstract: The present invention includes an intraoral tool, including one or more selected solid or inflatable inserts targeted to provide a low load prolonged stretch to orofacial musculature that may be coupled to tool handle or tool mounting bracket, wherein the intraoral tool is configured for a delivery of intraoral treatment, such as a stretch to a patient's facial injury or disorder and configured to permit manipulation of the insert in the patient's mouth.

Abstract: A self-massage roller having a bottle, a covering, and, optionally, a removable cap. The bottle provides a vessel for holding liquids. The covering includes a base layer and a plurality of nubs. The base layer overlays the outer surface of the bottle. Each nub in the plurality of nubs protrudes from the base layer in a direction radially away from the outer surface of the bottle. Each nub is a massage element, and the plurality of nubs forms a textured surface for myofascial release of certain muscles of the user. In another version, each nub is attached directly to the outer surface of the bottle without an intervening base layer. In versions with a cap, the cap may include a flip-up spout, or it may have a plunger valve that opens upon pulling the plunger outward and closes upon pushing in the plunger.

Abstract: An integrated lower back treatment system is provided. The system includes a central core. The system also includes attachment devices positionable on longitudinal ends of the core. The system further includes a strap, wherein an end of the strap connects with a longitudinal end of the core with the attachment device and an opposite end of the strap connects to an opposite longitudinal end of the core with another attachment device. Additionally, the system includes padding, wherein the padding assembly includes padding arranged to allow the padding to connect and form a shape over the core and wherein the padding has differing firmness characteristics such that when the padding is rotated about a longitudinal axis of the core, a user of the integrated lower back treatment system will experience different firmness values dependent upon a position of the rotated padding on a lower back of the user.

Abstract: A pet mobility carrier assembly for a disabled animal having either a rear leg disability or a front leg disability. The assembly includes a carrier base with a perimeter surface, a carrier animal support removably disposed on the carrier base, and at least three rollers connected to the carrier base that provides multi-directional movement to the pet mobility carrier assembly when on a floor.

Abstract: Devices and methods for assisting and guiding a person with visual and/or hearing impairment. In various embodiments there is a computer-guided, motorized walking stick. Preferably, at least one wheel at the distal end of the stick, and in contact with the ground, can be steered or pivoted over a range of angles, and thus establish a desired direction. In yet other embodiments there are one or more powered wheels that further drive the walking stick in the desired direction. Various algorithms are disclosed for providing instructions to the computer controller by way of various input devices. Still further embodiments include various types of sensors that provide data to the computer with regards to objects proximate to the walking stick.

Abstract: A personal care appliance is provided that includes an applicator head that includes at least a first applicator surface and a second applicator surface, each being configured to contact a skin surface of a user; an appliance body having a motor assembly for oscillating the applicator at a first frequency corresponding to the first applicator surface and a second frequency corresponding to the second applicator surface.

Abstract: In some embodiments, an affixed group of pharmaceutical vials with frangible connectors includes: a plurality of pharmaceutical vials arranged as a group of pharmaceutical vials, each of the plurality of pharmaceutical vials shaped and positioned to minimize a total volume of the group of pharmaceutical vials, each of the pharmaceutical vials including at least one external side with a surface configured to reversibly mate with a corresponding external side and a surface of an adjacent pharmaceutical vial; and a plurality of frangible connectors, wherein at least one frangible connector is affixed to the surface of at least two of the plurality of pharmaceutical vials within the group of pharmaceutical vials, and at least one frangible connector is affixed to each of the plurality of pharmaceutical vials.

Abstract: A syringe adapter is provided. The adapter includes a housing having a first end and a second end positioned opposite the first end. The housing may include a first portion and a second portion connected to the first portion. The first end of the housing can include a connector configured to be secured to a syringe barrel. The adapter also includes a cannula positioned within the housing and a seal arrangement including a membrane positioned within the housing and movable within the housing. The first portion of the housing can be connected to the second portion via axial and radial interference between the first portion and the second portion of the housing.

Abstract: The invention is a hollow nipple containing a side-entry tube and aperture that solves the problem of administering fluid medicines to infants or babies by combining the comfort of a common baby bottle, containing accustomed milk or formula, with the use of an industry common, over-the-counter oral medicine syringe by allowing for the syringe to be inserted into the side-entry tube and aperture so that the medicine can mix with the milk or formula and be quickly consumed while the care provider has the option of manually regulating the flow of the medicine into the nipple. The invention therefore avoids the need for administering such fluid medicine directly into the mouth, or even mixing it into the contents of the bottle where the medicine may not be fully or timely consumed. The invention has applications not only with human infants and babies but also in the field of animal care.

Abstract: Lipid-based delivery vehicles are provided. Nanoparticulate compositions typically including a p21 activated kinase (PAK) inhibitor and a lipid-based delivery vehicle are also provided. In preferred embodiments, the lipid-based delivery vehicle is a liposome, most preferably a sterically-stabilized liposome. Typically the lipid-based delivery vehicle includes one or more phospholipids, and optionally a sterol. In some embodiments, at least one of the phospholipids is PEGylated. In particular embodiments, the lipid-based delivery vehicle includes DSPC, DSPE-PEG2000, and cholesterol. In specific embodiments, the ratio of DSPC, DSPE-PEG, and cholesterol is 9:1:5. The nanoparticulate composition typically includes a PAK inhibitor, preferably a PAK-1 inhibitor such as IPA-3 or a derivative, prodrug, or pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone.

Abstract: This invention discloses methods and composition to form biodegradable polymer implant arrays in the live tissue. Artificial cavities are created in the live tissue by using laser ablation, oscillating needle, microneedle array and other methods. The cavities are then filled with biodegradable polymer solution. The solvent in the polymer solution is dissipated in the tissue to form a biodegradable polymer implant in artificial cavities. The cavities and implants formed are arranged to form of an array of implants. The biodegradable polymer in the cavity can also be loaded with drug to form biodegradable drug delivery array in the live tissue.

Abstract: The present invention relates to chemical and biological warfare agent decontaminating compositions and methods for using the same to decontaminate animal skin and wounds thereon exposed to the agents. The compositions may comprise a peracid, a hydroperoxide, and a peroxyacid.

Abstract: A method of treating noninfectious diarrhea in an HIV positive subject includes administering a dose of ibuprofen to the HIV positive subject at regular intervals until stool consistency is improved, diarrhea is alleviated, or the number of bowel movements per day are decreased. The dose is 400 mg of ibuprofen administered every 6 hours. The method may additionally include diagnosing the subject with noninfectious diarrhea, determining the subject does not have certain comorbidities, and/or determining that the subject is not taking any non-steroidal anti-inflammatory drugs. The method may additionally include after administering the ibuprofen, administering a clear liquids diet to the subject, administering an electrolyte supplement to the subject, and/or monitoring the subject for any bleeding from the gastrointestinal tract until stool consistency is improved, until diarrhea is alleviated, or until the number of bowel movements per day are decreased.

Abstract: The disclosure provides methods for treating or limiting development age-related macular degeneration, comprising (a) a GPR143 receptor agonist, including but not limited to L-DOPA, L-DOPA analogues, or a pharmaceutically acceptable salt thereof, and (b) melatonin, a melatonin analogue, or a pharmaceutically acceptable salt thereof, and related compositions.

Abstract: The present invention relates to the field of skin rejuvenation. Specifically, the present invention provides compositions and methods for promoting skin rejuvenation using a toll-like receptor 3 (TLR3) agonist and retinoic acid or derivatives thereof. In a specific embodiment, a method for treating wrinkles in a subject comprises the steps of (a) administering to the area of the subject comprising a wrinkle a composition comprising an effective amount of retinoic acid or a derivative thereof; and administering to the area of the subject comprising a wrinkle a composition comprising an effective amount of a TLR3 agonist.

Abstract: Topical dosages and formulations of chloroprocaine and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly during ophthalmic procedures or in response to ophthalmic abrasions or trauma.

Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.

Abstract: In some aspects, the techniques described herein relate to a topical dermatologic acne treatment method using a cream. The treatment method uses two steps, first providing a bactericidal component and second providing a skin revitalizing complex. The bactericidal component clears the acne causing bacteria. The subsequent skin revitalizing complex revitalizes and conditions the skin and aids in return of natural skin flora and microbiome to prevent subsequent outbreaks. The skin revitalizing complex can include a variety of components such as: niacinamide, retinol, bakuchiol, green coffee bean extract, green tea extract, epilobium fleischeri extract, citric acid, dimethicone, and pentaerythrityl tetracaprylate. The skin revitalizing complex restores natural elasticity and oil production of the skin, decrease sebum production, and provide necessary conditioning of the skin to provide for the natural skin flora and microbiome to repopulate and flourish on a surface of the skin.

Abstract: The invention relates to psychoactive medicines including 2C-B, methylone, MBDB, their respective metabolites, isomers, enantiomers, polymorphs, and analogues (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.

Abstract: The invention provides a compound of formula (I) wherein: A, B, C, D, W, X, Y and Z are each independently selected from H and OH; or a salt thereof; for use in the treatment and/or prophylaxis of a condition, disease or disorder in a subject, wherein the compound or salt is orally administered to a subject in a daily amount of from 2.8 to 6.6 mmol per day, over a period of at least 21 days. Also are provided are the compound of formula (I) for use in increasing mitophagy and/or autophagy, maintaining and/or improving muscle function and administration as a dietary, nutritional and/or health supplement.

Abstract: Provided herein are oral dosage forms comprising a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).

Abstract: The present invention provides relatively low pH, stable, pharmaceutically acceptable and ophthalmologically suitable compositions comprising effective amounts of pilocarpine and brimonidine compounds for treating an ocular condition, wherein compositions demonstrate a significant difference in the amount or rate of one or more pharmaceutical ingredient(s) absorbed or retained by ocular tissue or compared to reference composition(s) with similar compositional characteristics but having a significantly higher pH. In aspects compositions are characterizable by other elements, e.g., the inclusion of benzalkonium chloride, a limited amount of sodium chloride, or both. In embodiments, compositions are free of both a borate and a citrate buffer. Compositions provided by the invention surprisingly demonstrate pharmaceutically acceptable stability when stored under controlled room temperature conditions for an extended period of time.

Abstract: In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds.

Abstract: The invention provides a p38 MAPK inhibitor of Formula I, or a pharmaceutically acceptable salt or solvate thereof: for use in the treatment or prevention of hypercytokinemia in a human patient; wherein R is C1-3alkyl, optionally substituted by one or more halo, NR1R2 or hydroxy, and R1and R2 are independently H, halo or C1-3alkyl, optionally substituted by one or more F. Also provided are compositions for use in the treatment or prevention of hypercytokinemia comprising the p38 MAPK inhibitor of Formula I; and methods for treating or preventing hypercytokinemia in a human patient in need thereof comprising administering to the patient a therapeutically or prophylactically effective amount of a p38 MAPK inhibitor of Formula I. The invention also provides a p38 MAPK inhibitor and an antimicrobial agent, such as an antiviral agent, for use in the treatment or prevention of hypercytokinemia.

Abstract: This present invention relates to pharmaceutical composition comprising Deutetrabenazine. The invention also relates to the methods of preparation of the composition having improved stability and dissolution profile and used for the treatment of chorea associated with Huntington disease and tardive dyskinesia.

Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: The present disclosure relates to pharmaceutical solid forms and pharmaceutical compositions comprising ibutamoren or a pharmaceutically acceptable salt thereof, and methods for administering to a pediatric subject for treating growth hormone deficiency.

Abstract: The invention relates to a composition comprising a HIF-1a activity potentiating agent for use in a method of preventing or treating hair loss, wherein the HIF-1a activity potentiating agent is an iron chelator, preferably Deferiprone. The invention further relates to a composition for topical application, comprising a HIF-1a activity potentiating agent that is an iron chelator. Furthermore, the invention relates to a method for cosmetic treatment or prevention of hair loss, comprising topical application of a composition comprising a HIF-1a activity potentiating agent that is an iron chelator to an area of skin.

Abstract: This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors for treatment of subjects with relapsing multiple sclerosis.

Abstract: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.

Abstract: The present invention includes methods for treating a proliferative disorder comprising administering a therapeutically effective amount of crenolanib or a salt thereof in combination with pharmaceutical agent targeting apoptosis pathway proteins wherein the crenolanib and other agent are provided at least one of sequentially or concomitantly in a subject for use in the treatment of the proliferative disease, wherein the subject is a human subject.

Abstract: Disclosed herein are methods of treating neurological or psychiatric diseases or disorders using a combination of bupropion and dextromethorphan. Related compositions and dosage forms are also described.

Abstract: The invention provides methods of treatment of heart failure with reduced ejection fraction (HFrEF) using modified forms of trimetazidine, such as CV-8972 and CV-8814.

Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.

Abstract: This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.

Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.

Abstract: Compounds, compositions, and methods of treatment and prevention of HIV, including HIV-1 and HIV-2, Dengue, and Chikungunya infection are disclosed. The compounds are TREM-1 inhibitors. Combinations of these TREM-1 inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, JAK inhibitors, macrophage depleting agents, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV, Dengue, or Chikungunya virus in an infected patient.

Abstract: The present invention provides, inter alia, methods for treating, preventing, or ameliorating the effects of a lymphoid malignancy, such as those associated with a mutated phosphatase and tensin homolog (PTEN) gene, or T-cell acute lymphoblastic leukemia (T-ALL). These methods include administering to a subject an effective amount of a phosphoinositide 3-kinase-delta (PI3K?) inhibitor and a phosphoinositide 3-kinase-gamma (PI3K?) inhibitor. The present invention also provides pharmaceutical compositions for treating the effects of a lymphoid malignancy. This invention further provides a method for identifying a subject who may benefit from co-treatment with a PI3K? inhibitor and a PI3K? inhibitor. This method includes determining from a sample of the subject whether the subject has a mutated PTEN gene. Additionally, this invention provides methods for identifying a compound that has both PI3K? and PI3K? inhibitory activity.

Abstract: The present invention relates to a pediatric powder for reconstitution as suspension for oral administration comprising a therapeutically effective amount of an antiviral agent or pharmaceutical acceptable salt or derivative thereof, in particular Valaciclovir in complex with an ion exchange resin in a specific ratio in order to obtain a palatable and child-friendly product. It also relates to a process for the preparation thereof.

Abstract: Disclosed herein are “paraxanthine-BHB” compositions including a combination of: (1) paraxanthine; (2) a BHB ketone body component such as beta-hydroxybutyrate (BHB) salts, BHB esters or BHB acid; and (3) optionally a dietetically or pharmaceutically acceptable carrier. A BHB precursor such as 1,3-butanediol can be used in addition to or instead of BHB. Also disclosed herein are methods of using such compositions for producing desired physiological effects, such as enhanced cognitive flexibility, improved sustained attention, improved working memory, and neuroprotection in a mammal. In addition to such improved mental acuity characteristics, the compositions can also beneficially increase resting energy expenditure (resting metabolic rate), enhancing fat loss principally through ketosis while promoting muscle formation and maintenance, as well as modulating lethargy/lightheadedness when entering a ketogenic state.

Abstract: Provided herein are compositions for reducing symptoms of post-traumatic stress disorder. The compositions include a combination of an N-methyl-D-aspartate (NMDA) receptor antagonist and an anti-depression agent.

Abstract: The present invention discloses a pharmaceutical composition, wherein the pharmaceutical composition is an injectable or infusable pharmaceutical composition, the pharmaceutical composition comprising: a) a pharmaceutically acceptable solvent, b) a first compound comprising diclofenac and/or lornoxicam or a pharmaceutically acceptable salt or solvate thereof, c) a second compound comprising metamizole or tramadol or a pharmaceutically acceptable salt or solvate thereof, and d) a third compound selected as at least one benzodiazepine or a pharmaceutically acceptable salt or solvate thereof, the pharmaceutical composition further comprising a cortisone derivative or a pharmaceutically acceptable salt or solvate thereof.